The Clinical Efficacy Of Pegylated Interferon Combined With Ribavirin In Treating Hepatitis C Fibrosis Based On Systemate Review

Objective: To analyze the clinical efficacy of pegylated interferon combined with ribavirin in treating hepatitis C fibrosis by systemate review.Methods: Computer retrieval CNKI,Wanfang database,VIP database,PubMed,Medline,Embase and Cochrane Library published in domestic and foreign journals with pegylated interferon combined with Libavirin RCT since the construction of the library literature to December 31,2016.Screening the articles according to the specified inclusion criteria and exclusion criteria,was used the Jadad score method for quality analysis.The hyaluronic acid,type ? procollagen peptide,type ?collagen,laminin,alanine transferase,aspartate transferase and adverse effect were used as evaluation indexes,The RevMan 5.3 software provided by the Cochrane Collaboration was used for Meta-analysis.If the final result was high homogeneity,combined the effect of fixed variable model.If not,combined the effect of random variable model.Using the weighted mean differences as an outcome variable.The interval estimate about 95% confidence interval.Results: The research contain 11 clinical RCT,the results of Meta-a nalysis showed that:(1)Peg-IFN-alpha-2a+Ribavilin was better than theconventional liver protection treatment of hepatitis C fibrosis.PC? was improved [Z=10.39(P<0.00001),WMD=-62.69,95%CI:(-74.52,-50.86)],H A was improved [Z=4.03(P<0.0001),WMD=-52.71,95%CI:(-78.34,-27.08)],LN was improved [Z=4.2(P<0.0001,WMD=-43.21,95%CI:(-63.35,-23.06)],?-C was improved [Z=2.21(P=0.03,WMD=-28.89,95%CI:(-55.62,-2.17)].(2)Peg-IFN-alpha-2a+Ribavirinr egimen was better than IFN-alpha-2a+Ribavirin in treating hepatitis C fibrosis.HA was improved [Z=7.66(P<0.00001),WMD=-59.33,95%CI:(-74.51,-44.14)],PC? was improved[Z=10.18(P<0.00001),WMD=-33.61,95%CI:(-40.08,-27.14)],?C was imp-roved [Z=15.72(P<0.00001),WMD=-17.57,95%CI:(-19.76,-15.38)],LN was improved [Z=7.11(P<0.00001),WMD=39.00,95%CI:(-49.76,-28.24)],ALT was decreased [Z=8.15(P<0.00001),WMD=-28.27,95%CI:(-35.07,-21.46)],AST was decr-eased [Z=10.38(P<0.00001),WMD=-24.03,95%CI:(-28.57,-19.49)].(3)Adverse reactions: Mainly in fever,fatigue,dizziness,headach-e,muscle ache,nausea,vomiting and other flu-like symptoms,and the different levels of platelet,leukocytes and neutrophils reduced bone mar-row suppression performance,general symptoms were mild,can be rel-ieved by symptomatic treatment,does not affect thesubjects tocomplete follow up treatment,one study appeared insomnia sympto-ms,no serio-us adverse reaction was found.Conclusions: According to the Meta analysis of pegylated interferon combined with ribavirin in the treatment of hepatitis C fibrosis,the p-reliminary draw the following conclusions:(1)Peg-IFN-alpha-2a+ Ribavirin improve factors associated with hepatic C fibrosis.(2)Peg-IFN-alp-ha-2a+Ribavirin against hepatic fibrosis and improve the liver function was better than IFN-alpha-2a+Ribavirin.(3)Peg-IFN-alpha-2a+Ribavirin is a safe treatment.However,this study has some limitations,the reliabil-ity of the conclusions in this study wasn't completely enough.Howeve-r,moer samples,multi-center,and high-quality RCTs are required for further verification.